|
G |
Alb |
albumin |
affects binding |
ISO |
Alizarin Red S binds to ALB protein |
CTD |
PMID:18968587 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
|
G |
Alb |
albumin |
affects binding |
ISO |
chromotrope 2R binds to ALB protein |
CTD |
PMID:19347248 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance |
ISO |
BAX protein results in increased susceptibility to Acridine Orange |
CTD |
PMID:16177561 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA |
CTD |
PMID:16814760 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Acridine Orange results in increased stability of and results in increased activity of TP53 protein |
CTD |
PMID:16177561 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance |
ISO |
BAX protein results in increased susceptibility to Acridine Orange |
CTD |
PMID:16177561 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA |
CTD |
PMID:16814760 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Acridine Orange results in increased stability of and results in increased activity of TP53 protein |
CTD |
PMID:16177561 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein] Benzophenoneidum results in increased expression of ALDH1A1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Ano6 |
anoctamin 6 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ANO6 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ARAF protein |
CTD |
PMID:28722353 |
|
NCBI chr X:1,227,392...1,292,356
Ensembl chr X:1,227,392...1,239,073
|
|
G |
Atp6ap2 |
ATPase H+ transporting accessory protein 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ATP6AP2 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:10,183,983...10,210,948
Ensembl chr X:10,183,068...10,210,918
|
|
G |
Ccdc22 |
coiled-coil domain containing 22 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC22 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:14,898,296...14,910,244
Ensembl chr X:14,898,296...14,910,244
|
|
G |
Ccdc39 |
coiled-coil domain 39 molecular ruler complex subunit |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC39 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:116,665,651...116,703,354
Ensembl chr 2:116,665,261...116,703,350
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CD44 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Chtf18 |
chromosome transmission fidelity factor 18 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CHTF18 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COMMD1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501
|
|
G |
Cops7b |
COP9 signalosome subunit 7B |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COPS7B protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:87,238,132...87,263,967
Ensembl chr 9:87,238,375...87,263,967
|
|
G |
Cul3 |
cullin 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CUL3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
|
|
G |
Dynlt1 |
dynein light chain Tctex-type 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of DYNLT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:46,887,017...46,893,956
Ensembl chr 1:46,887,017...46,893,881
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of EIF4G3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363
|
|
G |
Fastkd2 |
FAST kinase domains 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of FASTKD2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:65,166,148...65,188,184
Ensembl chr 9:65,168,228...65,188,174
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
EXP |
Benzophenoneidum results in increased phosphorylation of H2AX protein |
CTD |
PMID:37527026 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hook3 |
hook microtubule-tethering protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HOOK3 protein |
CTD |
PMID:28722353 |
|
NCBI chr16:65,954,293...66,058,812
Ensembl chr16:65,954,350...66,061,338
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HSD17B7 protein |
CTD |
PMID:28722353 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Htt |
huntingtin |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HTT protein |
CTD |
PMID:28722353 |
|
NCBI chr14:75,845,836...75,996,094
Ensembl chr14:75,845,836...75,995,070
|
|
G |
Iqgap3 |
IQ motif containing GTPase activating protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of IQGAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:173,542,151...173,583,956
Ensembl chr 2:173,542,110...173,583,956
|
|
G |
Kifap3 |
kinesin-associated protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of KIFAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr13:76,127,702...76,264,654
Ensembl chr13:76,127,696...76,264,650
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]; Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein |
CTD |
PMID:28722353 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MAP2K4 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MBD3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
increases expression |
EXP |
Benzophenoneidum results in increased expression of MKI67 protein |
CTD |
PMID:37527026 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Noa1 |
nitric oxide associated 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NOA1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:30,835,264...30,851,294
Ensembl chr14:30,835,247...30,851,293
|
|
G |
Nup62 |
nucleoporin 62 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NUP62 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:95,298,995...95,314,902
Ensembl chr 1:95,295,526...95,315,174
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PLCG1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Ppp4r1 |
protein phosphatase 4, regulatory subunit 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PPP4R1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:105,391,271...105,450,626
Ensembl chr 9:105,391,412...105,450,633
|
|
G |
Prim2 |
DNA primase subunit 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRIM2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030
|
|
G |
Prom1 |
prominin 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PROM1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Prorp |
protein only RNase P catalytic subunit |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRORP protein |
CTD |
PMID:28722353 |
|
NCBI chr 6:72,669,659...72,762,419
Ensembl chr 6:72,670,847...72,762,416
|
|
G |
Shmt1 |
serine hydroxymethyltransferase 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SHMT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:45,468,698...45,490,833
Ensembl chr10:45,468,700...45,497,820
|
|
G |
Srsf11 |
serine and arginine rich splicing factor 11 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SRSF11 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:247,074,623...247,101,460
Ensembl chr 2:247,074,631...247,101,425
|
|
G |
Tbc1d15 |
TBC1 domain family, member 15 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TBC1D15 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:50,804,553...50,860,272
Ensembl chr 7:50,804,012...50,860,175
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TFAM protein |
CTD |
PMID:28722353 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Usp24 |
ubiquitin specific peptidase 24 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of USP24 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:121,080,687...121,210,321
Ensembl chr 5:121,080,470...121,210,311
|
|
G |
Washc5 |
WASH complex subunit 5 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of WASHC5 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:90,884,192...90,936,096
Ensembl chr 7:90,884,197...90,936,103
|
|
|
G |
Lig1 |
DNA ligase 1 |
decreases activity |
ISO |
Aurintricarboxylic Acid results in decreased activity of LIG1 protein |
CTD |
PMID:15134906 |
|
NCBI chr 1:74,165,688...74,204,400
Ensembl chr 1:74,165,842...74,204,413
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases activity |
ISO |
Aurintricarboxylic Acid results in decreased activity of OGG1 protein |
CTD |
PMID:26218629 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases activity |
EXP |
Azure A results in increased activity of GPT protein |
CTD |
PMID:33775737 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[Azure B affects the cleavage of APP protein] which results in decreased secretion of APP protein modified form; Azure B results in decreased expression of and affects the cleavage of APP protein |
CTD |
PMID:30500345 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bace1 |
beta-secretase 1 |
decreases activity |
ISO |
Azure B results in decreased activity of BACE1 protein |
CTD |
PMID:30500345 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
brazilein results in decreased expression of CCND1 mRNA; brazilein results in decreased expression of CCND1 protein |
CTD |
PMID:23948132 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
brazilein results in decreased expression of CTNNB1 protein |
CTD |
PMID:23948132 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
brazilein results in decreased expression of GSK3B protein modified form |
CTD |
PMID:23948132 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
brazilein promotes the reaction [SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein promotes the reaction [wortmannin results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein results in decreased expression of and results in decreased activity of MMP2 protein; SB 203580 promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]; wortmannin promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein] brazilein results in decreased expression of MMP2 mRNA |
CTD |
PMID:23707804 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
brazilein results in decreased expression of and results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:23707804 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
brazilein results in decreased expression of RELA protein |
CTD |
PMID:23707804 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
brazilin results in increased expression of BAX protein |
CTD |
PMID:28063998 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
brazilin results in decreased expression of BCL2 protein |
CTD |
PMID:28063998 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [brazilin results in increased expression of BECN1 protein]; BECN1 inhibits the reaction [brazilin results in increased activity of CASP3 protein]; BECN1 inhibits the reaction [brazilin results in increased expression of PARP1 protein modified form]; RELA protein promotes the reaction [brazilin results in increased expression of BECN1 mRNA]; RELA protein promotes the reaction [brazilin results in increased expression of BECN1 protein] brazilin results in increased expression of BECN1 mRNA; brazilin results in increased expression of BECN1 protein |
CTD |
PMID:28063998 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
brazilin results in increased activity of CASP3 protein Acetylcysteine promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; BECN1 inhibits the reaction [brazilin results in increased activity of CASP3 protein] |
CTD |
PMID:28063998 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; BECN1 inhibits the reaction [brazilin results in increased expression of PARP1 protein modified form] |
CTD |
PMID:28063998 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
RELA protein promotes the reaction [brazilin results in decreased expression of SQSTM1 protein]; RELA protein promotes the reaction [brazilin results in increased expression of BECN1 mRNA]; RELA protein promotes the reaction [brazilin results in increased expression of BECN1 protein] |
CTD |
PMID:28063998 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
ISO |
brazilin results in decreased expression of SQSTM1 protein Acetylcysteine inhibits the reaction [brazilin results in decreased expression of SQSTM1 protein]; RELA protein promotes the reaction [brazilin results in decreased expression of SQSTM1 protein] |
CTD |
PMID:28063998 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
brilliant green results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:26177467 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
brilliant green results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:26177467 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
brilliant green results in decreased expression of CCND1 protein |
CTD |
PMID:26177467 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
decreases expression |
ISO |
brilliant green results in decreased expression of IKBKE protein |
CTD |
PMID:26177467 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
increases expression |
ISO |
brilliant green results in increased expression of LONP1 mRNA |
CTD |
PMID:21215310 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
brilliant green inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Txn1 |
thioredoxin 1 |
increases oxidation |
ISO |
brilliant green results in increased oxidation of TXN protein |
CTD |
PMID:21215310 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txn2 |
thioredoxin 2 |
decreases expression affects response to substance multiple interactions |
ISO |
brilliant green results in decreased expression of TXN2 protein TXN2 protein affects the susceptibility to brilliant green brilliant green results in increased oxidation of and results in increased degradation of TXN2 protein |
CTD |
PMID:21215310 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]] |
CTD |
PMID:30580027 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:32633567 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
EXP |
crocin inhibits the reaction [Blood Glucose results in increased expression of ATG5 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased expression of ATG5 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased expression of ATG5 protein]] |
CTD |
PMID:33021114 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in decreased expression of BAMBI mRNA] |
CTD |
PMID:32259551 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; crocin inhibits the reaction [Diazinon results in increased expression of BAX mRNA]; crocin inhibits the reaction [Diazinon results in increased expression of BAX protein]; crocin inhibits the reaction [Malathion results in increased expression of BAX protein] crocin inhibits the reaction [Zearalenone results in increased expression of BAX protein] crocin results in increased expression of BAX mRNA |
CTD |
PMID:23523949 PMID:26231423 PMID:27353299 PMID:32886819 PMID:32920515 PMID:35274200 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
[crocin co-treated with Paraquat] results in decreased expression of BCL2 mRNA; crocin inhibits the reaction [Zearalenone results in decreased expression of BCL2 protein] crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein] crocin results in decreased expression of BCL2 mRNA |
CTD |
PMID:26231423 PMID:31911963 PMID:32886819 PMID:32920515 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
crocin results in increased expression of BDNF mRNA; crocin results in increased expression of BDNF protein |
CTD |
PMID:24401376 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Blood Glucose results in increased expression of BECN1 protein]; crocin inhibits the reaction [Blood Glucose results in increased phosphorylation of BECN1 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased expression of BECN1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased expression of BECN1 protein]] |
CTD |
PMID:33021114 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
crocin results in decreased expression of BIRC5 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases expression increases cleavage |
EXP ISO |
crocin affects the reaction [Ethanol results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased cleavage of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased expression of CASP3 protein modified form]; crocin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; crocin inhibits the reaction [Ethanol results in increased activity of CASP3 protein]; crocin inhibits the reaction [Malathion results in increased cleavage of CASP3 protein] crocin results in increased activity of CASP3 protein crocin results in increased expression of CASP3 mRNA crocin inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA] Acetylcysteine inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein] |
CTD |
PMID:23523949 PMID:25637687 PMID:25899501 PMID:26807765 PMID:27353299 PMID:30672053 PMID:31911963 PMID:32886819 PMID:32920515 PMID:35085590 PMID:35274200 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
crocin results in increased activity of CASP8 protein |
CTD |
PMID:32886819 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
EXP ISO |
crocin inhibits the reaction [Diazinon results in increased cleavage of CASP9 protein]; crocin inhibits the reaction [Malathion results in increased cleavage of CASP9 protein] crocin results in increased activity of CASP9 protein |
CTD |
PMID:27353299 PMID:32886819 PMID:35274200 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases activity increases activity |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]; crocin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; crocin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] crocin results in decreased activity of CAT protein crocin inhibits the reaction [Patulin results in increased activity of CAT protein]; crocin inhibits the reaction [Zearalenone results in increased activity of CAT protein] crocin results in increased activity of CAT protein |
CTD |
PMID:25899501 PMID:26231423 PMID:26584762 PMID:29409856 PMID:32886819 PMID:32920515 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
crocin results in decreased expression of CCND1 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
EXP |
crocin inhibits the reaction [Diazinon results in increased activity of CKM protein] |
CTD |
PMID:23523949 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
crocin results in increased expression of and results in increased phosphorylation of CREB1 protein |
CTD |
PMID:24401376 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
crocin inhibits the reaction [Diazinon affects the localization of CYCS protein] |
CTD |
PMID:23523949 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases activity |
EXP |
crocin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYP2E1 mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CYP2E1 protein] crocin results in decreased activity of CYP2E1 protein |
CTD |
PMID:25899501 PMID:32633567 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Foxp2 |
forkhead box P2 |
increases expression |
ISO |
crocin results in increased expression of FOXP2 protein |
CTD |
PMID:36988377 |
|
NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of GLO1 protein] |
CTD |
PMID:30580027 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; crocin inhibits the reaction [Cisplatin results in increased activity of GPT protein] crocin inhibits the reaction [Zearalenone results in increased expression of GPT protein] |
CTD |
PMID:26231423 PMID:32259551 PMID:32633567 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of HMOX1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
EXP |
crocin inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA] |
CTD |
PMID:25637687 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
crocin inhibits the reaction [Doxorubicin results in decreased expression of IL10 protein] |
CTD |
PMID:26807765 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] |
CTD |
PMID:24709313 PMID:26807765 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; crocin inhibits the reaction [Ethanol results in decreased expression of IL6 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of IL6 protein] crocin results in decreased expression of IL6 mRNA |
CTD |
PMID:25637687 PMID:25899501 PMID:29409856 PMID:32633567 PMID:32886819 PMID:32920515 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:29409856 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
crocin affects the expression of and affects the phosphorylation of JAK2 protein |
CTD |
PMID:32886819 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of KEAP1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
EXP |
crocin inhibits the reaction [Diazinon results in decreased expression of LDLR mRNA] |
CTD |
PMID:24132704 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
[Quercetin co-treated with crocin] inhibits the reaction [Blood Glucose results in increased lipidation of MAP1LC3B protein]; crocin inhibits the reaction [Blood Glucose results in increased lipidation of MAP1LC3B protein]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:33021114 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
EXP ISO |
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK1 protein] crocin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:24132704 PMID:28689058 PMID:32886819 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
EXP ISO |
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK3 protein] crocin results in decreased phosphorylation of MAPK3 protein crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA] |
CTD |
PMID:24132704 PMID:28689058 PMID:30580027 PMID:32886819 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions decreases expression |
EXP ISO |
crocin inhibits the reaction [bisphenol A results in increased expression of MIR122 mRNA] crocin results in decreased expression of MIR122 |
CTD |
PMID:28689058 PMID:36988377 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir29b1 |
microRNA 29b-1 |
increases expression multiple interactions |
EXP |
crocin results in increased expression of MIR29B1 mRNA Cisplatin inhibits the reaction [crocin results in increased expression of MIR29B1 mRNA]; crocin inhibits the reaction [Cisplatin results in decreased expression of MIR29B1 mRNA] |
CTD |
PMID:32259551 |
|
NCBI chr 4:59,650,987...59,651,067
Ensembl chr 4:59,650,986...59,651,067
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions |
ISO |
MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein] |
CTD |
PMID:35085590 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
crocin inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:25637687 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
crocin results in decreased expression of MYC mRNA |
CTD |
PMID:32886819 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycn |
MYCN proto-oncogene, bHLH transcription factor |
decreases response to substance multiple interactions decreases expression |
ISO |
MYCN results in decreased susceptibility to crocin crocin results in decreased expression of and results in decreased stability of MYCN mRNA; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of PARP1 protein] crocin results in decreased expression of MYCN protein |
CTD |
PMID:30672053 |
|
NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 protein] |
CTD |
PMID:32259551 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of NFE2L2 protein]; crocin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32259551 PMID:32920515 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of NQO1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ostm1 |
osteoclastogenesis associated transmembrane protein 1 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr20:46,071,657...46,187,049
Ensembl chr20:46,153,075...46,187,023
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
MYCN protein inhibits the reaction [crocin results in increased cleavage of PARP1 protein] |
CTD |
PMID:30672053 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
crocin inhibits the reaction [Carbon Tetrachloride results in decreased expression of PPARG protein] |
CTD |
PMID:32633567 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkab1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
multiple interactions |
EXP |
crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased phosphorylation of PRKAB1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased phosphorylation of PRKAB1 protein]] |
CTD |
PMID:33021114 |
|
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
crocin results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn4 |
protein tyrosine phosphatase, non-receptor type 4 |
multiple interactions increases expression |
ISO |
MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein] |
CTD |
PMID:35085590 |
|
NCBI chr13:30,772,012...30,952,340
Ensembl chr13:30,776,682...30,952,170
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein]; crocin inhibits the reaction [Streptozocin results in increased expression of RELA protein] |
CTD |
PMID:29409856 PMID:32920515 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Smad2 |
SMAD family member 2 |
decreases expression multiple interactions |
EXP |
crocin results in decreased expression of SMAD2 protein Cisplatin inhibits the reaction [crocin results in decreased expression of SMAD2 protein]; crocin inhibits the reaction [Cisplatin results in increased expression of SMAD2 protein] |
CTD |
PMID:32259551 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
EXP |
crocin inhibits the reaction [Malathion results in increased expression of SNCA mRNA]; crocin inhibits the reaction [Malathion results in increased expression of SNCA protein] |
CTD |
PMID:35274200 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Spry2 |
sprouty RTK signaling antagonist 2 |
increases expression |
ISO |
crocin results in increased expression of SPRY2 protein |
CTD |
PMID:36988377 |
|
NCBI chr15:82,692,291...82,697,408
Ensembl chr15:82,692,143...82,698,009
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Blood Glucose results in decreased expression of SQSTM1 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in decreased expression of SQSTM1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in decreased expression of SQSTM1 protein]] |
CTD |
PMID:33021114 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
crocin affects the expression of and affects the phosphorylation of STAT3 protein |
CTD |
PMID:32886819 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Blood Glucose results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein]; crocin promotes the reaction [Quercetin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]]; crocin promotes the reaction [Quercetin inhibits the reaction [Blood Glucose results in increased expression of TGFB1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein]]; Quercetin promotes the reaction [crocin inhibits the reaction [Blood Glucose results in increased expression of TGFB1 protein]] |
CTD |
PMID:29409856 PMID:32259551 PMID:32633567 PMID:33021114 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased expression of TGFBR1 protein] |
CTD |
PMID:32259551 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TLR4 protein] |
CTD |
PMID:29409856 PMID:32259551 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; crocin inhibits the reaction [Ethanol results in decreased expression of TNF protein] crocin results in decreased expression of TNF mRNA |
CTD |
PMID:25637687 PMID:25899501 PMID:26807765 PMID:32633567 PMID:32886819 PMID:32920515 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of GLO1 protein]; crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]] |
CTD |
PMID:30580027 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
crocin inhibits the reaction [Doxorubicin results in increased expression of TNNT2 protein] |
CTD |
PMID:26807765 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
crocin inhibits the reaction [Paraquat results in increased expression of TRP53 mRNA]; crocin inhibits the reaction [Zearalenone results in increased expression of TRP53 protein] |
CTD |
PMID:26231423 PMID:31911963 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Vgf |
VGF nerve growth factor inducible |
increases expression |
EXP |
crocin results in increased expression of VGF protein |
CTD |
PMID:24401376 |
|
NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]] |
CTD |
PMID:24535435 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
Gentian Violet promotes the reaction [TP53 protein binds to BBC3 promoter]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]] |
CTD |
PMID:24535435 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Gentian Violet results in decreased expression of BCL2 protein |
CTD |
PMID:27373978 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Gentian Violet results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:26177467 PMID:27373978 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Gentian Violet results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:26177467 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Gentian Violet results in decreased expression of CCND1 protein |
CTD |
PMID:26177467 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Gentian Violet promotes the reaction [TP53 protein binds to CDKN1A promoter]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA] |
CTD |
PMID:24535435 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Gentian Violet inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
decreases expression |
ISO |
Gentian Violet results in decreased expression of IKBKE protein |
CTD |
PMID:26177467 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Gentian Violet results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
Gentian Violet inhibits the reaction [NOX1 protein results in decreased activity of TP53 protein] |
CTD |
PMID:24535435 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Gentian Violet results in increased cleavage of PARP1 protein |
CTD |
PMID:24535435 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Prdx3 |
peroxiredoxin 3 |
multiple interactions |
ISO |
Gentian Violet promotes the reaction [Thiostrepton affects the expression of PRDX3 protein modified form] |
CTD |
PMID:22761781 |
|
NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Gentian Violet inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
multiple interactions |
ISO |
[Gentian Violet results in decreased phosphorylation of and affects the localization of STAT3 protein] inhibits the reaction [STAT3 protein binds to SOX2 promoter] |
CTD |
PMID:27373978 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Gentian Violet results in decreased phosphorylation of and affects the localization of STAT3 protein] inhibits the reaction [STAT3 protein binds to SOX2 promoter]; Gentian Violet results in decreased phosphorylation of and affects the localization of STAT3 protein |
CTD |
PMID:27373978 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions affects activity |
ISO |
Gentian Violet inhibits the reaction [NOX1 protein results in decreased activity of TP53 protein]; Gentian Violet promotes the reaction [TP53 protein binds to BBC3 promoter]; Gentian Violet promotes the reaction [TP53 protein binds to CDKN1A promoter]; Gentian Violet promotes the reaction [TP53 protein binds to TP53AIP1 promoter]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]; Gentian Violet promotes the reaction [TP53 protein results in increased expression of CDKN1A mRNA]; Gentian Violet results in increased stability of and results in increased activity of TP53 protein; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BAX mRNA]]; pifithrin inhibits the reaction [Gentian Violet promotes the reaction [TP53 protein results in increased expression of BBC3 mRNA]] Gentian Violet affects the activity of TP53 protein |
CTD |
PMID:24535435 PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn2 |
thioredoxin 2 |
decreases expression |
ISO |
Gentian Violet results in decreased expression of TXN2 protein |
CTD |
PMID:22761781 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Eosine Yellowish-(YS) inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Fast Green FCF inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:35901927 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]] |
CTD |
PMID:35901927 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine results in increased expression of BCL2 protein] |
CTD |
PMID:35901927 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine results in increased expression of BCL2L1 protein] |
CTD |
PMID:35901927 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine results in increased expression of CAT protein] |
CTD |
PMID:35901927 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine results in increased expression of GPX1 protein] |
CTD |
PMID:35901927 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:35901927 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
gallein inhibits the reaction [N(6)-cyclopentyladenosine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:35901927 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
gallein inhibits the reaction [Chloroquine affects the localization of SLC2A4 protein] |
CTD |
PMID:27160165 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects binding |
ISO |
Indigo Carmine binds to and results in increased activity of AHR protein Indigo Carmine binds to AHR protein |
CTD |
PMID:11425848 PMID:15001395 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein |
CTD |
PMID:23429044 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein |
CTD |
PMID:23429044 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO EXP |
Indigo Carmine results in increased activity of CYP1A1 protein Indigo Carmine results in increased expression of CYP1A1 mRNA Indigo Carmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:15001395 PMID:15882963 PMID:18493746 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein |
CTD |
PMID:23429044 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
Merbromin results in decreased activity of CA2 protein |
CTD |
PMID:16858005 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Merbromin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Methylene Blue results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
multiple interactions |
ISO |
Methylene Blue inhibits the reaction [Sodium Cyanide results in increased phosphorylation of ATP1A2 protein] |
CTD |
PMID:31173149 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BAX protein] |
CTD |
PMID:31428839 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 protein] |
CTD |
PMID:31428839 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
ISO |
Methylene Blue inhibits the reaction [Sodium Cyanide results in increased phosphorylation of CACNA1C protein] |
CTD |
PMID:31173149 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Nitroglycerin results in increased expression of CALCA mRNA] |
CTD |
PMID:11919648 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
ISO |
Methylene Blue results in increased activity of G6PD protein |
CTD |
PMID:1901343 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GCLC mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of GCLC mRNA] |
CTD |
PMID:24556215 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GCLM mRNA |
CTD |
PMID:24556215 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP mRNA]; Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP protein] |
CTD |
PMID:24556215 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Glrx |
glutaredoxin |
multiple interactions |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GLRX mRNA |
CTD |
PMID:24556215 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Glrx2 |
glutaredoxin 2 |
multiple interactions |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GLRX2 mRNA |
CTD |
PMID:24556215 |
|
NCBI chr13:55,481,875...55,504,737
Ensembl chr13:55,482,694...55,492,831
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [manganese chloride results in increased secretion of GNRH1 protein] |
CTD |
PMID:17290048 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Methylene Blue inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of HMOX1 mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of HMOX1 mRNA] Methylene Blue results in increased expression of HMOX1 protein |
CTD |
PMID:24556215 PMID:25943564 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ICAM1 protein] |
CTD |
PMID:31428839 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL17A protein] |
CTD |
PMID:31428839 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL6 protein] |
CTD |
PMID:31428839 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Methylene Blue inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Maob |
monoamine oxidase B |
multiple interactions decreases activity |
ISO |
Methylene Blue inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] Methylene Blue results in decreased activity of MAOB protein |
CTD |
PMID:21554916 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression multiple interactions decreases phosphorylation increases expression |
ISO |
Methylene Blue results in decreased expression of MAPT protein [Methylene Blue co-treated with MAPT protein mutant form] affects the localization of NFE2L2 protein; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GCLC mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GCLM mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GLRX mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of GLRX2 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of HMOX1 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NFE2L2 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NQO1 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of PRDX6 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of TXN2 mRNA; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of TXNRD2 mRNA; Methylene Blue affects the reaction [MAPT protein mutant form affects the expression of TXNRD1 mRNA]; Methylene Blue affects the reaction [MAPT protein mutant form results in increased expression of TXN mRNA]; Methylene Blue co-treated with [MAPT protein mutant form results in increased expression of NOS2 mRNA]; Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP mRNA]; Methylene Blue inhibits the reaction [MAPT protein mutant form results in increased expression of GFAP protein] Methylene Blue results in decreased phosphorylation of MAPT protein modified form Methylene Blue results in increased expression of MAPT mRNA |
CTD |
PMID:16930453 PMID:24556215 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Paraquat results in increased expression of MPO protein]; Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of MPO protein] |
CTD |
PMID:25943564 PMID:31428839 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
[Methylene Blue co-treated with MAPT protein mutant form] affects the localization of NFE2L2 protein; [Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NFE2L2 mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of GCLC mRNA]; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of HMOX1 mRNA]; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of NQO1 mRNA] Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:24556215 PMID:31428839 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Methylene Blue co-treated with [MAPT protein mutant form results in increased expression of NOS2 mRNA] Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of NOS2 protein] |
CTD |
PMID:24556215 PMID:31428839 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of NQO1 mRNA; NFE2L2 gene mutant form inhibits the reaction [Methylene Blue results in increased expression of NQO1 mRNA] |
CTD |
PMID:24556215 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
increases activity |
ISO |
Methylene Blue results in increased activity of PGD protein |
CTD |
PMID:1901343 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Prdx6 |
peroxiredoxin 6 |
multiple interactions |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of PRDX6 mRNA |
CTD |
PMID:24556215 |
|
NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
ISO |
Methylene Blue inhibits the reaction [Sodium Cyanide results in increased activity of and affects the localization of PRKCE protein] |
CTD |
PMID:31173149 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions increases activity |
ISO |
oxophenylarsine inhibits the reaction [Methylene Blue results in increased activity of SLC2A1 protein] |
CTD |
PMID:19686715 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Methylene Blue inhibits the reaction [Nitroglycerin results in decreased expression of TNF protein] |
CTD |
PMID:11744139 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
Methylene Blue affects the activity of TP53 protein |
CTD |
PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
Methylene Blue affects the reaction [MAPT protein mutant form results in increased expression of TXN mRNA] |
CTD |
PMID:24556215 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txn2 |
thioredoxin 2 |
multiple interactions |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of TXN2 mRNA |
CTD |
PMID:24556215 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
Methylene Blue affects the reaction [MAPT protein mutant form affects the expression of TXNRD1 mRNA] |
CTD |
PMID:24556215 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
multiple interactions |
ISO |
[Methylene Blue co-treated with MAPT protein mutant form] results in increased expression of TXNRD2 mRNA |
CTD |
PMID:24556215 |
|
NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156
|
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO |
pararosaniline results in decreased activity of BCHE protein |
CTD |
PMID:16036213 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
pararosaniline inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases expression decreases activity |
ISO |
pararosaniline results in decreased expression of NR3C1 protein pararosaniline results in decreased activity of NR3C1 protein |
CTD |
PMID:19255438 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases activity |
ISO |
Rose Bengal results in decreased activity of ABCB1 protein |
CTD |
PMID:20041016 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
EXP |
Rose Bengal results in decreased activity of CYP19A1 protein |
CTD |
PMID:18310892 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Rose Bengal results in decreased activity of CYP3A4 protein |
CTD |
PMID:20041016 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
decreases response to substance |
EXP |
GSTA3 protein results in decreased susceptibility to Rose Bengal |
CTD |
PMID:1740415 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Iyd |
iodotyrosine deiodinase |
decreases activity |
ISO |
Rose Bengal results in decreased activity of IYD protein |
CTD |
PMID:24012475 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Rose Bengal results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Klkb1 |
kallikrein B1 |
multiple interactions decreases response to substance |
ISO |
7-Ala-angiotensin (1-7) inhibits the reaction [KLKB1 gene mutant form results in decreased susceptibility to Rose Bengal]; nimesulide inhibits the reaction [KLKB1 gene mutant form results in decreased susceptibility to Rose Bengal]; splitomicin inhibits the reaction [KLKB1 gene mutant form results in decreased susceptibility to Rose Bengal] |
CTD |
PMID:25339356 |
|
NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases activity |
ISO |
Rose Bengal results in decreased activity of UGT1A6 protein |
CTD |
PMID:20041016 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Direct Red 81 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects localization multiple interactions |
ISO EXP |
sudan III affects the localization of AHR protein [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased activity of CYP2C11 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased expression of CYP2C11 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased expression of CYP2C11 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP2B1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP2B2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP3A2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP3A23-3A1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B1 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B2 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A2 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A23-3A1 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A23-3A1 protein]; [sudan III binds to AHR protein] which results in decreased activity of CYP2C11 protein; sudan III binds to and results in increased activity of AHR protein [sudan III affects the localization of AHR protein] promotes the reaction [AHR protein binds to ARNT protein]; [sudan III affects the localization of AHR protein] which results in increased expression of CYP1A1 mRNA; sudan III binds to and results in increased activity of AHR protein |
CTD |
PMID:15585952 PMID:15788368 PMID:22287322 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
[sudan III affects the localization of AHR protein] promotes the reaction [AHR protein binds to ARNT protein] |
CTD |
PMID:22287322 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression increases activity multiple interactions |
ISO EXP |
sudan III results in increased expression of CYP1A1 mRNA sudan III results in increased expression of CYP1A1 mRNA; sudan III results in increased expression of CYP1A1 protein sudan III results in increased activity of CYP1A1 protein [sudan III affects the localization of AHR protein] which results in increased expression of CYP1A1 mRNA; NR1I3 protein promotes the reaction [sudan III results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:18418879 PMID:20308224 PMID:22287322 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
EXP |
sudan III results in increased expression of CYP1A2 protein |
CTD |
PMID:20308224 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions decreases expression |
EXP |
[sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP2B1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B1 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B1 protein]; sudan III results in decreased expression of and results in decreased activity of CYP2B1 protein sudan III results in decreased expression of CYP2B1 mRNA |
CTD |
PMID:15788368 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions decreases expression |
EXP |
[sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP2B2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B2 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B2 protein]; sudan III results in decreased expression of and results in decreased activity of CYP2B2 protein sudan III results in decreased expression of CYP2B2 mRNA |
CTD |
PMID:15788368 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions decreases expression |
EXP |
[sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased activity of CYP2C11 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased expression of CYP2C11 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased expression of CYP2C11 protein]; [sudan III binds to AHR protein] which results in decreased activity of CYP2C11 protein; sudan III results in decreased expression of and results in decreased activity of CYP2C11 protein sudan III results in decreased expression of CYP2C11 mRNA |
CTD |
PMID:15788368 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases expression |
EXP |
[sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP3A2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A2 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A2 protein]; sudan III results in decreased expression of and results in decreased activity of CYP3A2 protein sudan III results in decreased expression of CYP3A2 mRNA |
CTD |
PMID:15788368 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions decreases expression |
EXP |
[sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP3A23-3A1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A23-3A1 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A23-3A1 protein]; sudan III results in decreased expression of and results in decreased activity of CYP3A23-3A1 protein sudan III results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:15788368 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
decreases expression |
EXP |
sudan III results in decreased expression of CYP4A1 mRNA |
CTD |
PMID:15585952 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
decreases expression |
EXP |
sudan III results in decreased expression of CYP4A2 mRNA |
CTD |
PMID:15585952 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
decreases expression |
EXP |
sudan III results in decreased expression of CYP4A3 mRNA |
CTD |
PMID:15585952 |
|
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
EXP |
sudan III results in increased expression of NQO1 mRNA |
CTD |
PMID:20308224 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
NR1I3 protein promotes the reaction [sudan III results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:22287322 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
ISO EXP |
sudan III results in decreased expression of PPARA protein sudan III results in decreased expression of PPARA mRNA [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased activity of CYP2C11 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased expression of CYP2C11 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in decreased expression of CYP2C11 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP2B1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP2B2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP3A2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased activity of CYP3A23-3A1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B1 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B1 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B2 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP2B2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A2 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A2 protein]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A23-3A1 mRNA]; [sudan III binds to AHR protein] inhibits the reaction [[Clofibric Acid binds to PPARA protein] which results in increased expression of CYP3A23-3A1 protein] |
CTD |
PMID:15585952 PMID:15788368 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rxra |
retinoid X receptor alpha |
decreases expression |
ISO |
sudan III results in decreased expression of RXRA protein |
CTD |
PMID:15585952 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
Scarlet Red results in increased expression of CYP1A1 mRNA; Scarlet Red results in increased expression of CYP1A1 protein |
CTD |
PMID:18418879 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adh6 |
alcohol dehydrogenase 6 (class V) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
[Tartrazine co-treated with Erythrosine] affects the expression of CASP9 mRNA |
CTD |
PMID:32981412 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
EXP ISO |
Tartrazine results in decreased activity of CAT protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA |
CTD |
PMID:20678534 PMID:33819548 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein |
CTD |
PMID:23429044 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein |
CTD |
PMID:23429044 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719
|
|
G |
Dnajc18 |
DnaJ heat shock protein family (Hsp40) member C18 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344
|
|
G |
Dnajc9 |
DnaJ heat shock protein family (Hsp40) member C9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Esr1 |
estrogen receptor 1 |
increases activity multiple interactions |
ISO |
Tartrazine results in increased activity of ESR1 protein fulvestrant inhibits the reaction [Tartrazine results in increased activity of ESR1 protein] |
CTD |
PMID:22562034 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gprc5b |
G protein-coupled receptor, class C, group 5, member B |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
EXP |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein |
CTD |
PMID:23429044 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[Tartrazine co-treated with Erythrosine] affects the expression of HAVCR1 mRNA |
CTD |
PMID:32981412 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Maf |
MAF bZIP transcription factor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Maff |
MAF bZIP transcription factor F |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapkapk3 |
MAPK activated protein kinase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Mmut |
methylmalonyl-CoA mutase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pah |
phenylalanine hydroxylase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G |
Pik3c2a |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472
|
|
G |
Pik3c2g |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961
|
|
G |
Prkd3 |
protein kinase D3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186
|
|
G |
Rdh16 |
retinol dehydrogenase 16 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sorl1 |
sortilin related receptor 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [Tartrazine results in increased expression of TFF1 mRNA] |
CTD |
PMID:22562034 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[Tartrazine co-treated with Erythrosine] results in increased expression of TNF mRNA |
CTD |
PMID:32981412 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions affects binding |
ISO |
[Dichlorvos results in increased phosphorylation of ACHE protein] inhibits the reaction [thioflavin T binds to ACHE protein]; [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in increased phosphorylation of ACHE protein] inhibits the reaction [thioflavin T binds to ACHE protein]; [thioflavin T binds to ACHE protein] inhibits the reaction [ACHE protein results in increased hydrolysis of Acetylthiocholine]; thioflavin T binds to and results in decreased activity of ACHE protein; thioflavin T inhibits the reaction [hopeahainol A binds to ACHE protein] |
CTD |
PMID:18423506 PMID:18602908 PMID:20493829 PMID:27297626 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
ISO |
Tolonium Chloride results in decreased activity of ACHE protein |
CTD |
PMID:33844597 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
decreases secretion |
ISO |
Tolonium Chloride results in decreased secretion of APP protein modified form |
CTD |
PMID:36027949 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
ISO |
Tolonium Chloride results in decreased expression of and results in decreased activity of BACE1 protein |
CTD |
PMID:36027949 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
decreases expression |
ISO |
Tolonium Chloride results in decreased expression of CDK5 protein |
CTD |
PMID:36027949 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Tolonium Chloride results in decreased expression of FYN protein |
CTD |
PMID:36027949 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression increases phosphorylation |
ISO |
Tolonium Chloride results in decreased expression of GSK3B protein Tolonium Chloride results in increased phosphorylation of GSK3B protein |
CTD |
PMID:36027949 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
Tolonium Chloride results in decreased expression of and results in decreased phosphorylation of MAPT protein |
CTD |
PMID:36027949 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
decreases phosphorylation |
ISO |
Tolonium Chloride results in decreased phosphorylation of PPP2CA protein |
CTD |
PMID:36027949 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Psen1 |
presenilin 1 |
decreases expression |
ISO |
Tolonium Chloride results in decreased expression of PSEN1 protein modified form |
CTD |
PMID:36027949 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|